



Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major

Aldo Filosa^{a,*}, Angela Vitrano^b, Paolo Rigano^c, Giuseppina Calvaruso^c, Rita Barone^c, Marcello Capra^d, Liana Cuccia^d, Francesco Gagliardotto^d, Lorella Pitrolo^c, Luciano Prossomariti^a, Maddalena Casale^a, Vincenzo Caruso^e, Calogera Gerardi^f, Saveria Campisi^g, Paolo Cianciulli^h, Michele Rizzoⁱ, Giuseppe D'Ascola^j, Angela Ciancio^k, Aurelio Maggio^c

^a U.O.D. Centro per le Microcitemie, A.O.R.N. "A. Cardarelli," Napoli, Italy

^b Dipartimento di Scienze Economiche, Aziendali e Statistiche, University of Palermo, Italy

^c U.O.C. Ematologia II con Talassemia, A.O.R. "Villa Sofia-V. Cervello," Palermo, Italy

^d U.O.C. Centro di Prevenzione Diagnosi e Cura della Talassemia, ARNAS Civico, Di Cristina, Benfratelli, Palermo, Italy

^e U.O.D. Talassemia, ARNAS Garibaldi, Catania, Italy

^f U.O.S. Talassemia, A.O.O.C.R. Sclafani, Italy

^g U.O.S. Centro Microcitemia, A.O. Umberto I, Siracusa, Italy

^h U.O. Talassemia, A.O.D. S. Eugenio, Roma, Italy

ⁱ U.O.C. Ematologia, A.O. S. Elia, Caltanissetta, Italy

^j Centro Microcitemia, A.O. B.M.M., Reggio Calabria, Italy

^k Ospedale Civile Madonna delle Grazie, U.O. Talassemia, Matera, Italy

ARTICLE INFO

Article history:

Submitted 16 February 2013

Revised 10 March 2013

Available online 28 April 2013

(Communicated by G. Stamatoyannopoulos, M.D., Dr. Sci., 11 March 2013)

Keywords:

Thalassemia major

Left ventricular ejection fraction (LVEF)

Deferiprone

Deferoxamine

Echocardiography

Chelation

ABSTRACT

Transfusion and iron chelation treatment have significantly reduced morbidity and improved survival of patients with thalassemia major. However, cardiac disease continues to be the most common cause of death. We report the left-ventricular ejection fraction, determined by echocardiography, in one hundred sixty-eight patients with thalassemia major followed for at least 5 years who received continuous monotherapy with deferoxamine ($N = 108$) or deferiprone ($N = 60$). The statistical analysis, using the generalized estimating equations model, indicated that the group treated with deferiprone had a significantly better left-ventricular ejection fraction than did those treated with deferoxamine (coefficient 0.97; 95% CI 0.37; 1.6, $p = 0.002$). The heart may be particularly sensitive to iron-induced mitochondrial damage because of the large number of mitochondria and its low level of antioxidants. Deferiprone, because of its lower molecular weight, might cross into heart mitochondria more efficiently, improving their activity and, thereby, myocardial cell function. Our findings indicate that the long-term administration of deferiprone significantly enhances left-ventricular function over time in comparison with deferoxamine treatment. However, because of limitations related to the design of this study, these findings should be confirmed in a prospective, randomized clinical trial.

© 2013 Elsevier Inc. All rights reserved.

Introduction

Thalassemia is one of the most common genetic diseases worldwide with at least 60,000 severely affected subjects being born every year [1]. Iron overload is a major concern in these patients because of the need for red cell transfusions. Transfusion and iron chelation treatment have significantly improved survival and reduced morbidity in thalassemia major during the last three decades [2,3].

The effectiveness of chelation therapy has improved as a result of the introduction of the oral iron chelators, deferiprone (DFP) and deferasirox

(DFX). Each chelator can be given as monotherapy. DFP and deferoxamine (DFO) have been widely used in combination.

The detection and management of cardiac damage have improved over the last 10 years because of cardiac magnetic resonance-T2* (CMR-T2*) imaging, a non-invasive tool with which to monitor cardiac function associated with iron body burden [4,5]. Cardiac disease continues to be the most common cause of death in patients with thalassemia major [3,6,7]. Chelation therapy is aimed at improving myocardial function, as judged by the left ventricular ejection fraction (LVEF).

A multicenter, randomized, open-label, long-term, study of sequential DFP–DFO compared to DFP has been reported in patients with thalassemia major to assess LVEF [8]. Improvement in the LVEF after 1-year of DFP treatment versus DFO was even found [9,10]. However, the effect

* Corresponding author at: U.O.D. "Centro per le Microcitemie" A.O.R.N. "A. Cardarelli," Via A. Cardarelli, 9 80131 Napoli, Italy. Fax: +39 0817472704.

E-mail address: aldo.filosa@aocardarelli.it (A. Filosa).

of DFP versus DFO on LVEF after long-term treatment has not so far been reported to our knowledge.

The aim of this study was to show if there was any difference in myocardial function as determined by 2-D echocardiography LVEF assessment when DFP and DFO treatment of thalassemia major patients was compared over a longer time period.

Materials and methods

Patients and treatment

This was a retrospective study of 168 patients with thalassemia major. Baseline clinical findings are shown in Table 1. All patients received at least 4 years of continuous monotherapy with DFO or DFP chelation treatment between September 30, 2002 and September 30, 2008. All enrolled subjects had echocardiographic study for LVEF. Among these, 108 received DFO treatment whereas 60 received DFP treatment (Table 1). DFO (Biofutura Pharma, Pomezia, Italy) was administered at 50 mg/kg per day by subcutaneous infusion (8–12 h) for 7 days. DFP (Apotex, Toronto, ON, Canada) was administered at 75 mg/kg, divided into three oral daily doses, for 7 days a week. Chelation treatment was stopped or dose was adjusted in case of occurrence of severe adverse events (SAEs). Compliance was assessed by counting the pills in each returned bag of DFP and by assessing the number of infusions of DFO registered on the electronic pump (CronoTM, Gene S.r.l., Italy).

Methods

LVEF was defined as the fraction of end-diastolic volume that is ejected by the left ventricle in each beat. It was measured by a single operator with two-dimensional (2-D) echocardiography assessments dividing the stroke volume by the end-diastolic volume in each patient (Vivid S5, Gems Ultrasound, Tirat Carmel, Israel). Two-dimensional echocardiography was used to determine the LVEF and volumes (single plane area-length method), and to calculate right ventricular end-diastolic and end-systolic areas by planimetry from the four-chamber view, according to previous recommendations [11]. The diagnosis of heart disease was based on standard clinical and instrumental findings including echocardiography and electrocardiogram [12]. Liver iron content (LIC) was determined on liver biopsies with an atomic spectrophotometer. Liver biopsy was performed only in patients on interferon treatment for chronic C hepatitis [13].

Statistical models

The generalized estimating equations (GEE) model was used [14] to evaluate if there was a statistically significant variation of LVEF over

time (four consecutive years) in the DFP versus DFO treated-groups and if this variation in the LVEF was statistically different between the two treated groups. LVEF values consisted of repeated observations over time on the same patient. These measurements, taken on the same patient, may not be independent one from another. One appropriate model, taking into account for the issue that repeated measurements might be correlated, is the generalized estimating equations (GEE) model [14]. This model includes the treatment-effect (treatment), the time-effect (time) and the treatment-by-time interaction effect (treatment \times time) of the considered variables. This approach was implemented using the “xtgee” procedure in the Stata 11 software (Stata Corporation, College Station, TX, USA). These findings are reported on Table 2 and Fig. 1. Moreover, yearly LVEF%, in both chelation groups divided by <55 and >55 , was reported in Table 3. Patient baseline clinical findings were reported with means and standard deviations (SD) for continuous variables and as proportions for dichotomous variables. All of the statistical analyses were performed under code at the Dipartimento di Scienze Economiche, Aziendali e Statistiche, Università di Palermo (Italy).

Results

All patients were over 13 years of age (Table 1). The prevalence of males was higher in the DFP treatment group (Table 1). Among the 168 patients, 108 received DFO and 60 received DFP chelation treatment (Table 1). Baseline hematological, cardiac, and body iron burden findings, evaluated as serum ferritin level, LIC, total number of blood transfusions, arrhythmia, HCV-RNA positivity, and mean age at the start of chelation treatment were not significantly different between the two treated groups (Table 1). Presence of cirrhosis showed a statistically significant difference, at baseline, between DFP versus DFO group (Table 1). Compliance was $92 \pm 7\%$ (range 37–100%) and $70 \pm 6\%$ (range 25–100%) in the DFP versus the DFO treatment groups, respectively. The serum ferritin levels at the end of the study were 1.4 ± 0.96 versus 1.6 ± 0.91 mg/L ($p < 0.01$) in DFO compared to DFP, respectively. The pre-transfusional Hb level was not statistically different between the two chelation groups ($t = 1.6$, $p = 0.12$), excluding this finding as a possible bias of the study.

The statistical analysis, evaluated by GEE model, indicated that the DFP treated group had a significant increase over time of mean LVEF in comparison with the DFO treated group (Coefficient 0.97, 95% CI 0.37; 1.6, $p = 0.002$, Table 2 and Fig. 1). No statistically significant variation was found for the DFO-group over time (coefficient -0.43 , 95% CI $(-1.2; 0.32)$, $p = 0.26$, Table 2 and Fig. 1).

The coefficient of the treatment-effect, indicating the difference between treatments, showed that there was not a statistically significant difference of LVEF between the two treated groups (coefficient -0.96 , 95% CI $-3.6; 1.7$), $p = 0.47$, Table 2 and Fig. 1). Table 3 showed that in the patients with a LVEF less than 55%, half (3 of 6) of DFP-treated group had an improved LVEF at the end of the study. Indeed, no

Table 1
Baseline findings in the 168 patients included in this retrospective cohort study.

Findings	DFO-group	DFP-group	p-Value
No. pts (168)	108	60	
Females no. (%)	55(51)	22 (37)	0.25
Age in years	32 ± 8.0	31 ± 7.0	0.26
Hemoglobin, g/L*	9 ± 0.83	9 ± 0.87	0.91
ALT, IU/L*	53 ± 39	50 ± 38	0.71
LIC, g/g per dw	3.3 ± 3.8	2.9 ± 2	0.61
Total transfusion, L/kg per year	9 ± 3	8.7 ± 2.1	0.51
Mean ferritin, mg/L	1.5 ± 1.1	1.7 ± 0.84	0.37
Mean basal EF $<55\%$ (no.)	45 ± 8.0 (26)	52 ± 2.0 (6)	0.05
Basal mean ejection fraction	58 ± 10	59 ± 4	0.23
Mean age at DFO starting, years	6 ± 6	6 ± 4	0.99
Splenectomy no. (%)	59 (60)	26 (44)	0.18
Cirrhosis no. (%)	21 (20)	5 (8.0)	0.01
Arrhythmia no. (%)	16 (15)	11(18)	0.81
HCV-RNA positive no. (%)	40 (42)	18 (30)	0.38

ALT, alanine aminotransferase; dw, dry weight; EF, ejection fraction; HCV, hepatitis C virus; IU, international units; LIC, liver iron content.

Table 2
GEE model to evaluate changes in mean ejection fraction levels in deferiprone (DFP)-group versus deferoximine (DFO)-group over time.

	Coefficients (SE*)	95% CI ^a	p-Value ^b
Intercept	58 (1)	(56–60)	<0.0001
Treatment ^c	-0.96 (1)	$(-4.0; 2.0)$	0.47
Time ^c	0.97 (0.31)	(0.37; 1.6)	<0.01
Treatment \times Time ^d	-0.43 (0.38)	$(-1.0; 32)$	0.26

^a SE = standard error, CI = confidence interval.

^b p-Value from null hypothesis coefficient = 0 by Wald's test.

^c Treatment is the variable indicating if a patient belongs to DFP-group or DFO-group; time is the variable indicating the consecutive years of observation, corresponding to $t = 1, 2, 3, 4$.

^d Treatment \times Time is the interaction effect between Treatment and Time.

Download English Version:

<https://daneshyari.com/en/article/2827329>

Download Persian Version:

<https://daneshyari.com/article/2827329>

[Daneshyari.com](https://daneshyari.com)